Advertisement

Pharmacy World & Science

, Volume 29, Issue 3, pp 164–166 | Cite as

Levetiracetam in three cases of progressive myoclonus epilepsy

  • Savvas Papacostas
  • Elena Kkolou
  • Eleftherios Papathanasiou
Case Report

Abstract

We present three unrelated cases of genetically confirmed progressive myoclonic epilepsy of the Unverricht–Lundborg type who were treated with Levetiracetam as adjunctive therapy for their myoclonus. All cases responded with decrease of their myoclonus and improvement of quality of life. Two were able to return to or continue their employment. Patients tolerated the drug well without side effects reported. Levetiracetam appears to be a useful antimyoclonic agent in cases of progressive myoclonic epilepsy and should be considered for adjunctive therapy.

Keywords

Epilepsy Levetiracetam Progressive Myoclonus Unverricht–Lundborg epilepsy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Notes

Acknowledgements

The authors of this manuscript report no conflicts of interest.

References

  1. 1.
    Crest C, Dupond S, Leguern E et al. Levetiracetam in progressive myoclonic epilepsy. Neurology 2004;62:640–3.PubMedGoogle Scholar
  2. 2.
    Kinrions P, Ibrahim N, Murphy K et al. Efficacy of levetiracetam in a patient with Undverricht-Lundborg progressive myoclonic epilepsy. Neurology 2003;60:1394–5.PubMedCrossRefGoogle Scholar
  3. 3.
    Magaudda A, Gelisse P, Genton P. Antimyoclonic effect of levetiracetam in 13 patients with Unverricht–Lundborg disease: clinical observations. Epilepsia 2004;45:678–81.PubMedCrossRefGoogle Scholar
  4. 4.
    Pennacchio LA, Lehesjoki A-E, Stone NE et al. Mutations in the gene encoding cystatin B in progressive myoclonic epilepsy (EPM1). Science 1996;271:1731–4.PubMedCrossRefGoogle Scholar
  5. 5.
    Genton P, Gelisse P. Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam. Neurology 2001;57:1144–5.PubMedGoogle Scholar
  6. 6.
    Niespodziany I, Klitgaard H, Margineanu D-G. Levetiracetam inhibits the high-voltage activated Ca2+ current in pyramidal neurons of rat hippocampal slices. Neurosci Lett 2001;306:5–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Rigo JM, Hans G, Nguyen L et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated current. Br J Pharmacol 2002;136:659–72.PubMedCrossRefGoogle Scholar
  8. 8.
    Lynch BA, Lambeng L, Nocka K et al. The synaptic vescicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 2004;101(26):9861–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Ben-Menachem E, Falter U, for the European Levetiracetam Study Group. Efficacy and tolerability of levetiracetam 3000 mg/day in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 2000;41:1276–83.Google Scholar
  10. 10.
    Kasteleijn-Nolst Trenite DGA, Hirsch E. Levetiracetam: preliminary efficacy in generalized seizures. Epileptic Disord 2003;5 Suppl 1:S39–S44.Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2006

Authors and Affiliations

  • Savvas Papacostas
    • 1
  • Elena Kkolou
    • 1
  • Eleftherios Papathanasiou
    • 1
  1. 1.The Cyprus Institute of Neurology & GeneticsNicosiaCyprus

Personalised recommendations